Literature DB >> 24412919

Up-regulation of miR-200b in biliary atresia patients accelerates proliferation and migration of hepatic stallate cells by activating PI3K/Akt signaling.

Yongtao Xiao1, Jun Wang2, Yingwei Chen3, Kejun Zhou3, Jie Wen3, Yang Wang3, Ying Zhou2, Weihua Pan2, Wei Cai4.   

Abstract

An increasing body of evidence suggests that miRNAs are involved in fibrotic process of several organs including heart, lung and kidney. It has been observed recently that aberrant expression of miR-200s are associated with hepatic fibrosis. However, the role and underlying mechanism of miR-200s in hepatic fibrogenesis remains unknown. Here, we investigate the role of miR-200b in the activation of immortalized human hepatic stallate cells (HSCs), LX-2 cells. We firstly found that miR-200b significantly enhanced proliferation and migration of LX-2 cells. Secondly, our findings showed that miR-200b enhanced the phosphorylation of Akt, a downstream effector of phosphatidyl-inositol 3-Kinase (PI3K). FOG2, as the targets of fly miR-8 and human miR-200s, directly binds to p85α and inhibits the activation of the PI3K/Akt pathway. Here, we showed that FOG2 protein levels in LX-2 cells were suppressed significantly by miR-200b mimics. FOG2 knockdown by siRNAs activated the PI3K/Akt signaling, which increased cell growth and migration that mimicked the effect of miR-200b. Conversely, LY294002, a highly selective inhibitor of PI3K, could block phosphorylation of Akt and effect of miR-200b. In addition, we showed that miR-200b enhanced the expression of matrix metalloproteinase-2 (MMP-2), which may increase the migration of LX-2 cells. Finally, our results indicated that the expression of miR-200b was unregulated in the biliary atresia (BA) and associated with liver fibrotic progression. These data suggest a potential mechanism for Akt activation through FOG2 down-regulation by miR-200b that can lead to HSC growth and migration. In view of the putative pathogenic role of miR-200b in HSCs, miR-200b may constitute a potential marker for HSC activation and liver fibrosis progression.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliary atresia; Hepatic stellate cells; Liver fibrosis; Migration; Proliferation; miR-200b

Mesh:

Substances:

Year:  2014        PMID: 24412919     DOI: 10.1016/j.cellsig.2014.01.003

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  30 in total

Review 1.  microRNA deregulation in keloids: an opportunity for clinical intervention?

Authors:  Xin Yu; Zheng Li; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-10-21       Impact factor: 6.831

2.  Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Yuyan Han; Lindsey Kennedy; Julie Venter; Heather Francis; Sharon DeMorrow; Paolo Onori; Pietro Invernizzi; Francesca Bernuzzi; Romina Mancinelli; Eugenio Gaudio; Antonio Franchitto; Shannon Glaser; Gianfranco Alpini
Journal:  FASEB J       Date:  2017-06-20       Impact factor: 5.191

3.  Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.

Authors:  Indsey Kennedy; Heather Francis; Fanyin Meng; Shannon Glaser; Gianfranco Alpini
Journal:  Liver Res       Date:  2017-04-26

Review 4.  Pathobiology of biliary epithelia.

Authors:  Angela C Cheung; Maria J Lorenzo Pisarello; Nicholas F LaRusso
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-15       Impact factor: 5.187

5.  Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b.

Authors:  Konstantina Kyritsi; Fanyin Meng; Tianhao Zhou; Nan Wu; Julie Venter; Heather Francis; Lindsey Kennedy; Paolo Onori; Antonio Franchitto; Francesca Bernuzzi; Pietro Invernizzi; Kelly McDaniel; Romina Mancinelli; Domenico Alvaro; Eugenio Gaudio; Gianfranco Alpini; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-05-12       Impact factor: 4.307

Review 6.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

7.  Yu Jin Pulvis inhibits carbon tetrachloride-induced liver fibrosis by blocking the MAPK and PI3K/Akt signaling pathways.

Authors:  Wei Wu; Haiyu Piao; Fushun Wu; Yong Han; Dongzhu An; Yanling Wu; Zhenhua Lin; Yingshi Piao; Jingchun Jin
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

8.  miR-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver.

Authors:  Zhiyong Liu; Jian Yi; Rong Ye; Jianping Liu; Qing Duan; Junqi Xiao; Fengen Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

9.  Beyond miR-122: Identification of MicroRNA Alterations in Blood During a Time Course of Hepatobiliary Injury and Biliary Hyperplasia in Rats.

Authors:  Rachel J Church; Monicah Otieno; James Eric McDuffie; Bhanu Singh; Manisha Sonee; LeRoy Hall; Paul B Watkins; Heidrun Ellinger-Ziegelbauer; Alison H Harrill
Journal:  Toxicol Sci       Date:  2015-11-26       Impact factor: 4.849

10.  Long Non-coding RNA Growth Arrest-specific Transcript 5 (GAS5) Inhibits Liver Fibrogenesis through a Mechanism of Competing Endogenous RNA.

Authors:  Fujun Yu; Jianjian Zheng; Yuqing Mao; Peihong Dong; Zhongqiu Lu; Guojun Li; Chuanyong Guo; Zhanju Liu; Xiaoming Fan
Journal:  J Biol Chem       Date:  2015-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.